To assess LC as a potential immunotherapeutic agent applied to patients with cancer, we first determined human CD8+ T cells (Fig. 5a) and found that LA inhibited the activation of anti-CD3/CD28-stimulated CD8+ T cells derived from the peripheral blood of healthy donors; however, this could be reversed by the addition of LC (Fig. 5b). The gene discussed is CD8A; the disease is cancer.